Search the Newsreel

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indicating a lack of activity …

BILI6453990 Latest News and Headlines

This page provides the latest news and headlines for Bilibili Inc.'s corporate bond, BILI6453990. It shows the bond's FINRA information and indicates that the market is currently closed with no trades. The site primarily serves as a financial data platform offering market insights, charts, …

Morgan Stanley Sticks to Their Buy Rating for Bilibili, Inc. Class Z (9626)

Morgan Stanley has reiterated its Buy rating for Bilibili, Inc. Class Z (9626) with a price target of HK$241.80. This aligns with a Strong Buy consensus from analysts, who have an average price target of HK$228.01. Bilibili recently reported a quarterly revenue of HK$7.4 …

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was July 10, 2026, with …

iBio Updates Governance Deadlines for 2026 Annual Meeting

iBio Inc. has set the date for its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of September 1, 2026. The company has adjusted key governance deadlines due to the meeting occurring earlier than the anniversary of the 2025 …

BILIBILI-W (09626) Stock Forum and Discussion

This article provides access to a stock forum and discussion for BILIBILI-W (09626). It serves as a platform for investors and interested parties to exchange information and opinions regarding the company's stock performance and related news.

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage biotech focused …

Bilibili Inc (BILI) Stock Down 5.1% -- Now Undervalued? GF Score: 68/100

Bilibili Inc (BILI) saw its stock drop 5.1% to $18.04, placing it 14.3% below its GF Value™ of $21.05, suggesting it is currently undervalued. The company's GF Score™ is 68/100, reflecting strengths in Valuation and Growth, but weaknesses in Profitability and Momentum. Despite the …

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these newly …

iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines

iBio, Inc. has announced the schedule for its 2026 Annual Meeting of Stockholders on October 14, 2026, with September 1, 2026, as the record date for voting eligibility. Due to the meeting being held more than 30 days earlier than the 2025 annual meeting, …

Citic Securities Reaffirms Their Buy Rating on Bilibili, Inc. Class Z (9626)

Citic Securities has reaffirmed its Buy rating on Bilibili, Inc. Class Z (9626), setting a price target of HK$212.00, while the shares closed recently at HK$137.80. The company reported a quarterly revenue of HK$7.4 billion and a net profit of HK$207.88 million for the …

Why Bilibili (BILI) Is Up 6.5% After Massive BML2026 ACGN Concert Engagement And What's Next

Is It Too Late to Buy Bilibili Inc (BILI) After 4.6% Rally? GF Value Says Undervalued

Bilibili Inc (BILI) shares rallied 4.6% to $18.28 on July 15, 2026, and according to GuruFocus' GF Value, the stock is considered "Modestly Undervalued." With a GF Score of 68/100, BILI shows strong valuation but struggles with profitability, and there have been no insider …

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn Continues - Share Repurchase Impact

Bilibili (BILI) Could Be 40% Undervalued Following Ad Growth And Buybacks

YIBITAS YOZGAT I - KAP Haberleri - 2026-07-09 tarihli

We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth

Bilibili Inc. Provides Update on Share Repurchase Program

9626 Forecast — Price Target — Prediction for 2027

Bilibili Inc. Announces New $300 Million Share Repurchase Program

REG - OptiBiotix Health - Result of AGM

Assessing Bilibili (BILI) Valuation After Recent Share Price Weakness And Conflicting Earnings Multiples

Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

I.B.I. Investment House Ltd (TLV:IBI) Is About To Go Ex-Dividend, And It Pays A 2.0% Yield

OptiBiotix Health plc (AIM: OPTI) Notice of Annual General Meeting

How Bilibili’s Q1 Profit Swing and Buyback Completion Will Impact Bilibili (BILI) Investors

Inhibikase Therapeutics (IKT) Holds Near Support Amid Modest Gains - Late Stage Breakouts

Inhibikase Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines - Slow Growth Warning

CICC Keeps Their Buy Rating on Bilibili, Inc. Class Z (9626)

Bilibili Q1 Earnings: Reflecting On The 'Sell' Quant Rating (NASDAQ:BILI)

Bilibili: Focus On User Additions And Margin Expansion

Benchmark reiterates Bilibili stock Buy rating on strong ad growth

Bilibili Q1 Earnings Call Highlights

BILIBILI ($BILI) Releases Q1 2026 Earnings

Bilibili Inc. Announces First Quarter 2026 Financial Results

Bilibili (BILI) Q1 Earnings Surpass Estimates